20 results
6-K
EX-99.1
VALN
Valneva SE
27 Nov 23
Current report (foreign)
12:03pm
for public health and therapeutic innovation”2.
Accelerated assessment reduces the timeframe for EMA’s CHMP to review a MAA once it is accepted for review
6-K
EX-99.1
VALN
Valneva SE
9 Nov 23
Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates
10:40am
for public health and therapeutic innovation”. A marketing application is also under review by Health Canada9.
If approved, VLA1553 could become the first
6-K
EX-99.1
VALN
Valneva SE
27 Oct 23
Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated Assessment
5:00pm
interest for public health and therapeutic innovation”.
VLA1553 is currently the first and only chikungunya vaccine candidate worldwide for which
20-F
vjlirzgl7h17u0zrc5i
24 Mar 22
Annual report (foreign)
12:32pm
424B4
m1t1uef95kt448z7
1 Nov 21
Prospectus supplement with pricing info
4:06pm
F-1
xjkf5mjmvkscb2u
26 Oct 21
Registration statement (foreign)
5:04pm
DRS
brza67qzh8hs i8zfn7
20 Oct 21
Draft registration statement
12:00am
424B4
gdsm 6oo7um
7 May 21
Prospectus supplement with pricing info
4:06pm
F-1/A
fl8pscz1jn fdx
5 May 21
Registration statement (foreign) (amended)
6:07am
F-1/A
p1zy3 q1zx5e46
29 Apr 21
Registration statement (foreign) (amended)
6:08am
F-1/A
jqybh5znk9842r7f
21 Apr 21
Registration statement (foreign) (amended)
5:06pm
F-1
sk69bnt
9 Apr 21
Registration statement (foreign)
4:06pm
F-1
EX-10.1
96u7dps3i8a3x2
9 Apr 21
Registration statement (foreign)
4:06pm
DRS/A
2bck4ud
24 Mar 21
Draft registration statement (amended)
12:00am
DRS/A
kie2wyv9 9o
24 Feb 21
Draft registration statement (amended)
12:00am
DRS/A
EX-10.1
agvqpsync6ofm
24 Feb 21
Draft registration statement (amended)
12:00am
DRS
ml7h7wuybso9ja5bx cq
15 Jan 21
Draft registration statement
12:00am
- Prev
- 1
- Next